Table 1 Clinical baseline characteristics
From: Developing serum proteomics based prediction models of disease progression in ADPKD
Screening Cohort (SC) | Internal/Temporal Cohort (ITC) | External Cohort (EC) | |
|---|---|---|---|
Patients, n | 214 | 408 | 173 |
Sex (Female %) | 56.5 | 57.4 | 57.8 |
Age (years), median (IQR) | 46.1 (16.9) | 48.2 (17.7) | 46.6 (17.5) |
eGFR (ml/min/m2), median (IQR) | 67.3 (44.5) | 65.0 (51.7) | 66.0 (46.6) |
TKV (ml), median (IQR) | 1315.5 (1300.0) | 1479.0 (1399.8) | 1415.0 (1335.0) |
Mayo classification, n | 212 | 392 | 169 |
1A | 2 | 14 | 8 |
1B | 62 | 118 | 33 |
1C | 75 | 140 | 68 |
1D | 58 | 87 | 41 |
1E | 15 | 33 | 19 |
CKD stage, n | 214 | 408 | 173 |
1 eGFR ≥ 90 ml/min/1.73m2 | 56 | 108 | 47 |
2 eGFR 60-89 ml/min/1.73m2 | 71 | 116 | 55 |
3 eGFR 30−59 ml/min/1.73m2 | 80 | 123 | 54 |
4 eGFR 15-29 ml/min/1.73m2 | 7 | 51 | 17 |
5 eGFR <15 ml/min/1.73m2 | 0 | 10 | 0 |
Hypertension, n | 152 | 161 | 171 |
No | 22 | 22 | 41 |
Yes | 130 | 139 | 130 |
Genotype, n | 115 | 175 | 162 |
PKD1, non-truncating | 19 | 37 | 55 |
PKD1, truncating | 64 | 79 | 75 |
PKD2 | 32 | 59 | 32 |
